Plasma and Platelet Transfusion for A-Negative Patients
For an A-negative patient, plasma products should be ABO-compatible (preferably A or AB plasma), while platelet products can be ABO-identical (A) when available, but ABO-mismatched platelets are acceptable with attention to plasma compatibility to avoid hemolytic reactions. 1
Plasma Transfusion Strategy
ABO Compatibility Requirements
- Prioritize plasma compatibility to prevent acute hemolytic transfusion reactions from incompatible antibodies
- For A-negative patients, acceptable plasma products include:
- First choice: Group A plasma (identical match)
- Second choice: Group AB plasma (universal plasma donor)
- Avoid: Group O or B plasma (contains anti-A antibodies that can cause hemolysis)
Rh Considerations for Plasma
- Plasma does not contain RBCs, so Rh matching is not required for plasma products
- No risk of RhD alloimmunization from plasma transfusion alone
Platelet Transfusion Strategy
ABO Matching Approach
While ABO-identical platelets are preferred, the evidence shows this is not always necessary or practical. The key distinction is between major (cellular) and minor (plasma) compatibility:
- Ideal: Group A platelets (ABO-identical)
- Acceptable alternatives when A platelets unavailable:
- Group O platelets (major compatible, but monitor for high-titer anti-A in plasma)
- Group AB platelets (minor compatible)
- Group B platelets (least preferred, both major and minor incompatible)
Critical Caveat: High-Titer Anti-A Risk
When transfusing Group O platelets to an A-negative patient, there is risk of hemolysis from high-titer anti-A antibodies in the donor plasma. 2, 3 This is particularly concerning with:
- Single-donor apheresis platelets (larger plasma volume ~200-300 mL)
- Multiple Group O platelet transfusions
Mitigation strategies:
- Use volume-reduced Group O platelets when possible
- Screen Group O donors for high-titer anti-A (though no standardized threshold exists in the US) 2
- Monitor for signs of hemolysis (hemoglobinuria, falling hemoglobin disproportionate to bleeding)
- Consider limiting volume of ABO-incompatible plasma per transfusion
RhD Immunization Prevention
Risk Assessment
The risk of RhD alloimmunization from platelet transfusion is now recognized as quite low (1.44% in recent data), significantly lower than historical estimates of 7.8-19%. 1 This is due to decreased RBC contamination in modern platelet products:
- Apheresis platelets: ~0.00043 mL RBCs
- Whole blood-derived platelets: ~0.036 mL RBCs
- Threshold for immunization: ~0.03 mL RBCs
When to Prevent RhD Alloimmunization
RhD alloimmunization prevention is NOT routinely necessary for all A-negative patients. 1
Selective prevention is recommended for:
- Female children and adolescents (particularly girls with future pregnancy potential)
- Women of childbearing age (<50 years) being treated with curative intent
- These patients may become pregnant after successful cancer treatment, risking hemolytic disease of the fetus and newborn
Prevention is generally NOT necessary for:
- Males of any age
- Post-menopausal women (>50 years)
- Patients with palliative/non-curative treatment goals
Prevention Methods (When Indicated)
Two acceptable approaches: 1
Exclusive use of RhD-negative platelets
- May be difficult to maintain with multiple transfusions
- Can compromise ABO-identical matching 4
RhD immunoprophylaxis (RhIG) when RhD-positive platelets given
- Dose: 20 mg (100 IU) protects against 1 mL of RBCs 1
- Timing: Before or immediately after transfusion; may be effective up to 72 hours post-exposure
- Route: Intravenous preparation preferred (e.g., WinRho SDF) to avoid hematoma risk in thrombocytopenic patients 5
- One dose may cover multiple platelet transfusions depending on timing and RBC content
Additional Considerations
Leukoreduction
All platelet and RBC products should be leukoreduced for patients expected to require multiple transfusions, particularly those with acute myeloid leukemia or other leukemias. 1 This reduces:
- Alloantibody-mediated platelet refractoriness
- Febrile transfusion reactions
- CMV transmission risk
In the US, most blood products are now universally leukoreduced at collection, eliminating need for bedside filtration.
Common Pitfall
Do not sacrifice ABO plasma compatibility in pursuit of RhD matching. The risk of acute hemolysis from ABO-incompatible plasma far exceeds the low risk of RhD alloimmunization. 4 Studies show that efforts to provide RhD-negative platelets to RhD-negative patients resulted in fewer patients receiving ABO-identical transfusions, which is the wrong trade-off.